Prevalence of the apolipoprotein e arg145cys dyslipidemia at-risk polymorphism in african-derived populations

American Journal of Cardiology

Volumn 113, Issue 2, 2014, Pages 302-308

  Abou Ziki, Maen D ^a,b   Strulovici Barel, Yael ^a   Hackett, Neil R ^a   Rodriguez Flores, Juan L ^a   Mezey, Jason G ^a,c   Salit, Jacqueline ^a   Radisch, Sharon ^a   Hollmann, Charleen ^a   Chouchane, Lotfi ^b   Malek, Joel ^b   Zirie, Mahmoud A ^d   Jayyuosi, Amin ^d   Gotto, Antonio M ^a   Crystal, Ronald G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (Qatar)

^c Program on Infrastructure Policy   (United States)

^d HAMAD MEDICAL CORPORATION   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4; ARGININE; C REACTIVE PROTEIN; CYSTEINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AFRICA SOUTH OF THE SAHARA; AFRICAN AMERICAN; ALLELE; ARTICLE; CARDIOVASCULAR RISK; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOMINANT INHERITANCE; DYSLIPIDEMIA; ETHNIC DIFFERENCE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; UNITED STATES;

EID: 84891631523     PISSN: 00029149     EISSN: 18791913     Source Type: Journal    
DOI: 10.1016/j.amjcard.2013.09.021     Document Type: Article

References (30)

1. J. Davignon, R.E. Gregg, and C.F. Sing Apolipoprotein E polymorphism and atherosclerosis Arteriosclerosis 8 1988 1 21
2. J.E. Eichner, S.T. Dunn, G. Perveen, D.M. Thompson, K.E. Stewart, and B.C. Stroehla Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review Am J Epidemiol 155 2002 487 495
3. R.W. Mahley, and S.C. Rall Jr. Type III hyperlipoproteinemia (dysbetalipoproteinemia): the role of apolipoprotein E in normal and abnormal lipoprotein metabolism C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle, The Metabolic and Molecular Bases of Inherited Disease 7th ed 1995 McGraw-Hill New York 1953 1980
4. R.W. Mahley, and S.C. Rall Jr. Apolipoprotein E: far more than a lipid transport protein Annu Rev Genomics Hum Genet 1 2000 507 537
5. H. Hunter-Zinck, S. Musharoff, J. Salit, K.A. Al-Ali, L. Chouchane, A. Gohar, R. Matthews, M.W. Butler, J. Fuller, N.R. Hackett, R.G. Crystal, and A.G. Clark Population genetic structure of the people of Qatar Am J Hum Genet 87 2010 17 25
6. A. Bener, M. Zirie, I.M. Janahi, A.O. Al-Hamaq, M. Musallam, and N.J. Wareham Prevalence of diagnosed and undiagnosed diabetes mellitus and its risk factors in a population-based study of Qatar Diabetes Res Clin Pract 84 2009 99 106
7. W.J. de Villiers, D.R. van der Westhuyzen, G.A. Coetzee, H.E. Henderson, and A.D. Marais The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance Arterioscler Thromb Vasc Biol 17 1997 865 872
8. Z.S. Ji, S. Fazio, and R.W. Mahley Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia J Biol Chem 269 1994 13421 13428
9. L.U. Gerdes, C. Gerdes, P.S. Hansen, I.C. Klausen, O. Faergeman, and J. Dyerberg The apolipoprotein E polymorphism in Greenland Inuit in its global perspective Hum Genet 98 1996 546 550
10. G. Feussner, H. Scharnagl, C. Scherbaum, J. Acar, J. Dobmeyer, J. Lohrmann, H. Wieland, and W. Marz Apolipoprotein E5 (Glu212 - >Lys): increased binding to cell surface proteoglycans but decreased uptake and lysosomal degradation in cultured fibroblasts J Lipid Res 37 1996 1632 1645
11. V.G. Shore, and B. Shore Heterogeneity of human plasma very low density lipoproteins: separation of species differing in protein components Biochemistry 12 1973 502 507
12. R.W. Mahley Heparan sulfate proteoglycan/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease Isr J Med Sci 32 1996 414 429
13. P. Cullen, A. Cignarella, B. Brennhausen, S. Mohr, G. Assmann, and E.A. von Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages J Clin Invest 101 1998 1670 1677
14. J.D. Smith, M. Miyata, M. Ginsberg, C. Grigaux, E. Shmookler, and A.S. Plump Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors J Biol Chem 271 1996 30647 30655
15. D.R. Riddell, A. Graham, and J.S. Owen Apolipoprotein E inhibits platelet aggregation through the L-arginine:nitric oxide pathway: implications for vascular disease J Biol Chem 272 1997 89 95
16. M.J. Mistry, M.A. Clay, M.E. Kelly, M.A. Steiner, and J.A. Harmony Apolipoprotein E restricts interleukin-dependent T lymphocyte proliferation at the G1A/G1B boundary Cell Immunol 160 1995 14 23
17. T. Vogel, N.H. Guo, R. Guy, N. Drezlich, H.C. Krutzsch, D.A. Blake, A. Panet, and D.D. Roberts Apolipoprotein E: a potent inhibitor of endothelial and tumor cell proliferation J Cell Biochem 54 1994 299 308
18. Y. Nakashima, A.S. Plump, E.W. Raines, J.L. Breslow, and R. Ross ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree Arterioscler Thromb 14 1994 133 140
19. K.H. Weisgraber, T.L. Innerarity, and R.W. Mahley Abnormal lipoprotein receptor-binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site J Biol Chem 257 1982 2518 2521
20. S.C. Rall Jr., and R.W. Mahley The role of apolipoprotein E genetic variants in lipoprotein disorders J Intern Med 231 1992 653 659
21. S.C. Rall Jr., K.H. Weisgraber, T.L. Innerarity, and R.W. Mahley Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects Proc Natl Acad Sci U S A 79 1982 4696 4700
22. P. Raven, G. Johnson, K.A. Mason, J.B. Losos, and S.S. Singer Genes within populations Biology 9th ed 2010 McGraw Hill New York 401 402
23. M. Rizzo, and K. Berneis Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? J Atheroscler Thromb 12 2005 237 239
24. J. Morganroth, R.I. Levy, and D.S. Fredrickson The biochemical, clinical, and genetic features of type III hyperlipoproteinemia Ann Intern Med 82 1975 158 174
25. C. Grunfeld, D.P. Kotler, R. Hamadeh, A. Tierney, J. Wang, and R.N. Pierson Hypertriglyceridemia in the acquired immunodeficiency syndrome Am J Med 86 1989 27 31
26. D. Periard, A. Telenti, P. Sudre, J.J. Cheseaux, P. Halfon, M.J. Reymond, S.M. Marcovina, M.P. Glauser, P. Nicod, R. Darioli, and V. Mooser Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors: the Swiss HIV Cohort Study Circulation 100 1999 700 705
27. Overview of race and Hispanic origin: 2010. 2010 Census Briefs 2011. Available at: http://www.census.gov/prod/cen2010/briefs/c2010br-02.pdf. Accessed on September 1, 2013.
28. 2009 World population data sheet. Population Reference Bureau 2011;1-19. Available at: http://www.prb.org/pdf09/09wpds-eng.pdf. Accessed on September 1, 2013.
29. P. Lohse, D.J. Rader, and H.B. Brewer Jr. Heterozygosity for apolipoprotein E-4Philadelphia(Glu13 - -Lys, Arg145 - -Cys) is associated with incomplete dominance of type III hyperlipoproteinemia J Biol Chem 267 1992 13642 13646
30. P. Lohse, W.A. Mann, E.A. Stein, and H.B. Brewer Jr. Apolipoprotein E-4Philadelphia (Glu13 - -Lys, Arg145 - -Cys): homozygosity for two rare point mutations in the apolipoprotein E gene combined with severe type III hyperlipoproteinemia J Biol Chem 266 1991 10479 10484